Objective:

To synthesize current evidence and explore the potential mechanisms of action of GLP-1 receptor agonists (GLP-1RAs) in treating ocular diseases, including diabetic retinopathy, glaucoma, and age-related macular degeneration.

Approach:

Key Findings:

• GLP-1RAs have shown potential beyond metabolic disorders, particularly in neuroprotection and anti-inflammatory effects, which could address limitations in current treatments for major ocular diseases like diabetic retinopathy, glaucoma, and age-related macular degeneration.

Interpretation:

GLP-1RAs may offer novel therapeutic avenues for managing ocular disorders due to their unique neuroprotective and anti-inflammatory properties, which existing treatments do not adequately address.

Limitations:

• The review is limited to studies published in English, which may introduce language bias.
• Exclusion of reviews, commentaries, and case reports may overlook relevant insights.

Conclusion:

GLP-1RAs represent a promising area of research for treating ocular diseases, warranting further investigation into their mechanisms and clinical applications, particularly in neuroprotection and inflammation.

Source

Based on findings from:

Exploring the Role of GLP-1 Receptor Agonists in Ocular Disorders: An In-Depth Analysis of Existing Studies and Future Directions

Yu Luo, Yanting Xia, Xiaohong Gong, Meiling Hao, Qiping Wei, Liang Liao. Bmc Ophthalmology, 2026.

https://link.springer.com/article/10.1186/s12886-025-04559-x

Attribution Notice

This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.